$RLFTF - NEWS - The inclusion of ZYESAMI™ in the

$RLFTF - NEWS - The inclusion of ZYESAMI™ in the I-SPY COVID-19 Trial follows a request from the U.S. Department of Health and Human Services and the Department of Defense for investigational drugs capable of targeting the most acutely ill patients with COVID-19. ZYESAMI™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for the treatment of Critical COVID-19 in patients with Respiratory Failure.

News link

https://www.prnewswire.com/news-releases/neur...04909.html

$MJ